Видео ютуба по тегу Nectin-4

Как действует Падцев при раке мочевого пузыря и мочевыводящих путей?
Как действует Падцев при раке мочевого пузыря и мочевыводящих путей?
Mechanisms and future directions for ADC therapies in bladder cancer
Mechanisms and future directions for ADC therapies in bladder cancer
The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B & More
The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B & More
Enfortumab Vedotin + Pembrolizumab: First-Line Breakthrough in Advanced Urothelial Cancer
Enfortumab Vedotin + Pembrolizumab: First-Line Breakthrough in Advanced Urothelial Cancer
In Their Own Words: Humphrey Fonge
In Their Own Words: Humphrey Fonge
[CORPORATE] LAUNCH OF ASTELLAS PADCEV
[CORPORATE] LAUNCH OF ASTELLAS PADCEV
Уротелиальный рак мочевого пузыря на 4-м ежегодном национальном саммите по ГМО
Уротелиальный рак мочевого пузыря на 4-м ежегодном национальном саммите по ГМО
RLTs in Bladder Cancer: Nectin-4 Targeting
RLTs in Bladder Cancer: Nectin-4 Targeting
Emerging biomarkers of response to EV in urothelial carcinoma
Emerging biomarkers of response to EV in urothelial carcinoma
Emerging biomarkers of response to ADCs in bladder cancer
Emerging biomarkers of response to ADCs in bladder cancer
Phase I trial of SHR-A2102, a nectin-4 targeted ADC, in urothelial carcinoma
Phase I trial of SHR-A2102, a nectin-4 targeted ADC, in urothelial carcinoma
NEXUS-01: LY4052031, a nectin-4 ADC, in urothelial carcinoma and other tumors
NEXUS-01: LY4052031, a nectin-4 ADC, in urothelial carcinoma and other tumors
#UromigosLive24 ADCs in UC Panel Part 4: Novel ADCs Including HER3 and Novel Nectin-4
#UromigosLive24 ADCs in UC Panel Part 4: Novel ADCs Including HER3 and Novel Nectin-4
Enfortumab Vedotin (Padcev) for bladder cancer
Enfortumab Vedotin (Padcev) for bladder cancer
Role of the Interleukin-1-Beta / Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) axis...
Role of the Interleukin-1-Beta / Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) axis...
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma
LY4101174, a novel nectin-4-targeting ADC in solid tumors
LY4101174, a novel nectin-4-targeting ADC in solid tumors
Phase II EPIC trial: enfortumab vedotin in advanced pancreatic adenocarcinoma
Phase II EPIC trial: enfortumab vedotin in advanced pancreatic adenocarcinoma
Sacituzumab govitecan and other ADCs in prostate cancer
Sacituzumab govitecan and other ADCs in prostate cancer
Enfortumab vedotin for the treatment of advanced urothelial cancer
Enfortumab vedotin for the treatment of advanced urothelial cancer